cover image: Everolimus (Afinitor) for Neuroendocrine Tumours of Gastrointestinal or Lung Origin

Premium

20.500.12592/6htfcd

Everolimus (Afinitor) for Neuroendocrine Tumours of Gastrointestinal or Lung Origin

2016

This Clinical Guidance is based on: a systematic review of the literature regarding Everolimus for NETs GIL conducted by the Endocrine Clinical Guidance Panel (CGP) and the pCODR Methods Team; input from patient advocacy groups; input from the Provincial Advisory Group; input from Registered Clinicians; and supplemental issues relevant to the implementation of a funding decision. [...] The objective of the systematic review is to evaluate the efficacy and safety of everolimus compared to relevant comparators (e.g. [...] In the absence of reliably effective therapeutic alternatives, there was consensus of the CGP that everolimus should be made available for the treatment of patients with incurable, non-functional well-differentiated neuroendocrine tumours of gastrointestinal or lung origin. [...] CNETS Canada conducted online surveys using SurveyMonkey and telephone interviews directed to patients and caregivers to collect both qualitative and quantitative information about the impact of NETs GIL on their lives and the effect of treatment. [...] The goal of the Global NETs Survey was to “increase understanding of the experiences, needs and challenges of NET patients, and to provide insights and learnings among countries and regions to advance NET care.” Below are key findings from the international survey.
health cancer caregivers medicine pharmacology therapy clinical trial chemotherapy medline clinical medicine systematic review society clinical diseases and conditions caregiver adverse effect abstract (summary) everolimus bloating carcinoid pancreatic afinitor carcinoid syndrome aphthous stomatitis
Pages
53
Published in
Ottawa, ON, CA

Related Topics

All